Cancel

The Brigham Board Review in Hematology and Oncology

Get ready for the ABIM exam in Hematology-Oncology by studying this Hematology-Oncology Board Review from Brigham and Women’s Hospital. The course includes sections on the Biology of Acute Leukemia and Myelodysplastic Syndromes, Symptom Management in Patients with Cancer, Hodgkin's Lymphoma, Pancreatic and Hepatobiliary Cancer, the Biology of Hematopoietic Stem Cell Transplantation, Cervical and Endometrial Cancer and the entire range of hematology and oncology topics covered on the Hematol...
CMEInfo

Expert Insights: Personalizing Multiple Myeloma Treatment for Maximum Benefit

The multiple myeloma treatment landscape is changing rapidly, and hematologist-oncologists are armed with an increasing number of therapeutic options in the frontline and salvage settings. This development holds promise for patients but increases the challenge of multiple myeloma management for clinicians. The current clinical focus is on determining the best combination of agents for each patient and personalizing regimens to patients based on biologic and genetic features of the disease. In ...
Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation

Unit 2: Risk Stratification and Adaptive Therapy in the Newly Diagnosed Patient with Multiple Myeloma

In this second installment of four activities, our Managing Myeloma team expert, Shaji Kumar, MD, professor of medicine at the Mayo Clinic College of Medicine and a consultant within the Division of Hematology at the Mayo Clinic in Rochester, Minnesota, discusses risk stratification in newly diagnosed multiple myeloma patients and the goals and/or uses of risk stratification with emphasis on the definition of the high-risk patient. Dr. Kumar explores the current and future uses of various risk...
MediCom Worldwide, Inc. (Kristen)

Unit 1: Diagnosis and Risk Stratification of Myeloma Today: Defining High-Risk Patients

In this first installment of four activities, join our Managing Myeloma team expert, Sagar Lonial, MD, professor and vice chair of clinical affairs within the Department of Hematology and Medical Oncology at the Winship Cancer Institute, Emory University School of Medicine in Atlanta, Georgia, for a discussion regarding IMWG updates to the criteria of diagnosing MM, and the rationale for these changes. He will discuss how to identify high-risk smoldering myeloma as well as high-risk multiple m...
MediCom Worldwide, Inc. (Kristen)

The Oncologist: What keeps oncologists from addressing palliative care early on with incurable cancer patients? –an active stance seems to be key

Learning objectives 1. Discuss openly with patients issues and decisions regarding the last phases of their lives. 2. Use your own empathy as an important nonmedical factor in the decision process. Background. Sympathetic and frank communication about the terminal nature of advanced cancer is important to improve patients’ prognostic understanding and, thereby, to allow for adjustment of treatment intensity to realistic goals; however, decisions against aggressive treatments are often m...
Society For Translational Oncology

IFIs: Epidemiological Trends, Antifungal Resistance, and Why Antifungal Therapy Fails in Patients with Invasive Mold Infections

Target audience The enduring activity is intended for health care professionals, particularly physicians, clinical microbiologists, researchers, nurse, nurse practitioners and pharmacists, specializing in prevention and management of fungal infections. Learning objectives Upon completion of the educational activity, participants should be able to: -Discuss the role of prophylaxis therapy in patients with invasive fungal infections (IFIs) -Review the emerging data on breakthrough and rel...
AKH Inc. Advancing Knowledge in Healthcare

Drug Interactions with Chemotherapy

Activity Description Participants in this webinar will learn the reasons for patient nonadherence to oral chemotherapy regimens, and how adherence can be improved. Faculty will review the pharmacokinetics of oral oncolytic drugs, such as methotrexate and vincristine, and will use case studies to illustrate potentially significant interactions with other drugs or foods, and how they can be prevented or managed if they occur. Strategies for educating patients about potential drug interactions...
ProCE

Biosimilars 101: The Science, Approval Process & Implications for Your Practice

Since their emergence in the early 1980s, biologic drugs have been increasingly viewed as the future of medicine. Biosimilars are “follow-on” reproductions of these complex molecules. By 2015, more than 30 branded biologics are expected to lose patent exclusivity, while the pool of biosimilars is expected to grow more than 20% per year. Now that the FDA has authority to approve biosimilars, they are expected to enter the U.S. market within the next 1 to 2 years. This CE supplement to th...
ProCE

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.